One of the more expensive supplements I have been advised to take is called BreastDefend from EcoNugenics. It costs about $89 for a 2 month supply.(Trust me that’s inexpensive compared to other supplements I take!)
Many of the ingredients in BreastDefend stand on their own and have been highlighted under the Super Supplements heading when you go to Complimentary Therapies on my main page, with the exception of the Scutellaria barbata herb, which is not available to the public as a single supplement.
“Using eight clinically tested compounds, this synergistic formula is scientifically proven to promote cellular health, promote healthy hormone modulation, and support healthy immune function.*
The proprietary blend contains the antioxidative flavanoid quercetin, turmeric rhizome extract (BCM-95®; 95% curcumin), Astragalus membranaceus root extract, Scutellaria barbata herb extract, and an advanced formulation of DIM (3,3′- diindolylmethane). DIM, an ingredient found in broccoli, has been researched for its ability to promote cellular health, and support healthy estrogen metabolism. The formula is completed by the addition of three powerful, botanically enhanced medicinal mushrooms for immune support.*”
The only ingredient in this formula that is not available to the general public is the Scutellaria barbata herb extract which is also known as Ban Zhi Lian.
The Chinese herb Ban Zhi Lian may not be in everyone’s lexicon, but to the 80 women with stage IV metastatic breast cancer, who are participating in the second phase of the BZL101 clinical trials, it represents hope and life.
According to TimeHealth:
For Bionovo, the drug discovery and development company in Emeryville, Calif., that’s behind BZL101, there’s hope. The trial is the first FDA-validated clinical study of a potential cancer drug derived from a Chinese medicinal herb, says Dr. Mary Tagliaferri, a co-founder of the company, former practicing acupuncturist and a breast-cancer survivor. “Sixty-two percent of chemotherapy drugs come from natural products, and plants have been the basis of almost every new class of medication,” she says. “It makes sense that these plants can act as anticancer agents.”
Cohen’s early observations about Ban Zhi Lian may have started out as a hunch, but they may hold up. In 1996, Cohen and Tagliaferri, along with Dr. Debu Tripathy, then a breast cancer specialist at the University of California, San Francisco, co-founded the Complementary and Alternative Medicine program at the university’s Carol Franc Buck Breast Care Center. Over the next several years, the trio amassed enough evidence about the herb’s anticancer properties — in lab tests of animals and breast-cancer cells, BZL101 caused apoptosis or cell death, according to Tagliaferri — to get a green light from the FDA to begin clinical trials.”